Paper37001036
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ and 20 others. Blood, 2023. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Papers, record 37001036. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37001036
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasm Recurrence, Local | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Humans | |
| Prognosis | |
| Retrospective Studies | |
| Positron-Emission Tomography | |
| Risk Factors | |
| Fluorodeoxyglucose F18 |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 203148/Z/16/Z | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 37347501 | A man's best friend is his PET. | https://conductscience.org/library/papers/37347501 |
Source PubMed
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28774879 | Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. | Blood | 2017 | https://conductscience.org/library/papers/28774879 | PubMed |
| 2 | 31710995 | Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. | Eur J Cancer | 2020 | https://conductscience.org/library/papers/31710995 | PubMed |
| 3 | 36306337 | Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. | Blood Adv | 2023 | https://conductscience.org/library/papers/36306337 | PubMed |
| 4 | 33278600 | Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†. | Ann Oncol | 2021 | https://conductscience.org/library/papers/33278600 | PubMed |
| 5 | 16754935 | Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16754935 | PubMed |
| 6 | 25981519 | Prediction models need appropriate internal, internal-external, and external validation. | J Clin Epidemiol | 2016 | https://conductscience.org/library/papers/25981519 | PubMed |
| 7 | 32232482 | International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. | Blood | 2020 | https://conductscience.org/library/papers/32232482 | PubMed |
| 8 | 34272315 | Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter? | J Nucl Med | 2022 | https://conductscience.org/library/papers/34272315 | PubMed |
| 9 | 35357901 | Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35357901 | PubMed |
| 10 | 32436212 | Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. | Br J Haematol | 2021 | https://conductscience.org/library/papers/32436212 | PubMed |
| 11 | 32680929 | Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. | J Nucl Med | 2021 | https://conductscience.org/library/papers/32680929 | PubMed |
| 12 | 34714558 | Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. | Hematol Oncol | 2022 | https://conductscience.org/library/papers/34714558 | PubMed |
| 13 | 30785937 | RaCaT: An open source and easy to use radiomics calculator tool. | PLoS One | 2019 | https://conductscience.org/library/papers/30785937 | PubMed |
| 14 | 3203132 | Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. | Biometrics | 1988 | https://conductscience.org/library/papers/3203132 | PubMed |
| 15 | 35406482 | Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35406482 | PubMed |
| 16 | 35146578 | Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/35146578 | PubMed |
| 17 | 31201248 | 18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. | J Nucl Med | 2020 | https://conductscience.org/library/papers/31201248 | PubMed |
| 18 | 26150440 | Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26150440 | PubMed |
| 19 | 30941463 | Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. | Eur J Nucl Med Mol Imaging | 2019 | https://conductscience.org/library/papers/30941463 | PubMed |
| 20 | 26936916 | Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26936916 | PubMed |
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42931850 | Organ-specific depth of response to CD19-directed CAR T-cell therapy in B-cell lymphomas. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42931850 | PubMed |
| 42910135 | Associations of Subcutaneous and Visceral Fat Areas with Progression-Free Survival in Patients with Diffuse Large B-Cell Lymphoma. | Int J Med Sci | 2026 | https://conductscience.org/library/papers/42910135 | PubMed |
| 42664000 | A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL. | Blood Adv | 2026 | https://conductscience.org/library/papers/42664000 | PubMed |
| 42636799 | Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42636799 | PubMed |
| 42420890 | 18F-FDG PET/CT radiomics combined with double-expressor status enhances prognostication and high-risk stratification in DLBCL. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42420890 | PubMed |
| 42414740 | Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42414740 | PubMed |
| 42360330 | PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42360330 | PubMed |
| 42326344 | Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42326344 | PubMed |
| 42322517 | Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma. | Radiol Med | 2026 | https://conductscience.org/library/papers/42322517 | PubMed |
| 41872336 | A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/41872336 | PubMed |
| 41786479 | Validation of an AI Method for Automated Lymphoma Metabolic Tumor Volume Segmentation Using a Public Benchmark PET/CT Dataset. | J Nucl Med | 2026 | https://conductscience.org/library/papers/41786479 | PubMed |
| 41689647 | A Lesion-adaptive Segmentation Approach for Tumor Delineation on FDG PET/CT in Diffuse Large B-cell Lymphoma Patients. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/41689647 | PubMed |
| 41260205 | A prognostic index integrating deep learning baseline PET/CT biomarkers and multi-omics profiling in diffuse large B cell lymphoma. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/41260205 | PubMed |
| 40995463 | Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. | Hemasphere | 2025 | https://conductscience.org/library/papers/40995463 | PubMed |
| 40900042 | Automatic Lugano staging for risk stratification in lymphoma: a multicenter PET radiomics and machine learning study with survival analysis. | Nucl Med Commun | 2025 | https://conductscience.org/library/papers/40900042 | PubMed |
| 40629066 | Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma. | Leukemia | 2025 | https://conductscience.org/library/papers/40629066 | PubMed |
| 40558299 | Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma with 18F-FDG PET/CT. | Curr Oncol | 2025 | https://conductscience.org/library/papers/40558299 | PubMed |
| 40518458 | Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis. | Eur J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40518458 | PubMed |
| 40506239 | Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024. | J Nucl Med | 2025 | https://conductscience.org/library/papers/40506239 | PubMed |
| 40492497 | Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma. | Oncologist | 2025 | https://conductscience.org/library/papers/40492497 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37001036
GET https://conductscience.org/api/papers/v1/37001036/authors?page=2